Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.
Allakos, a US-based developer of antibodies to treat conditions caused by excess production of inflammatory cells, has filed for a $75m initial public offering that could provide exits to Johns Hopkins University.
Founded in 2012, Allakos is working on a treatment called AK002 that will address eosinophil and mast cell related diseases. Eosinophil disorder causes cells that are responsible for releasing toxins to be overproduced, leading to an inflammation of tissue.
Mast cell-related diseases cause chemical mediators to be…
